B urn injury is the most severe form of trauma, accounting for ~330,000 deaths per year worldwide (1) ; this devastating injury affects nearly every organ system and leads to significant morbidity and mortality (2) . The dearth of biomarkers for early assessment of outcome following burn, trauma, or critical illness forces clinicians to rely on parameters, such as heart rate, hypotension, and hyperglycemia to monitor the patient's clinical trajectory. These measures do not allow prediction of patient outcome. Discovery of a biomarker or proteomic signature comprising the expression of a series of proteins would enable early assessment of patient risk for succumbing to burn, trauma, or critical illness. This signature would facilitate early identification of patients requiring aggressive therapy to improve their chances of survival.
The development of new high-throughput proteomic technologies facilitates the identification of protein profiles that can serve as diagnostic biomarkers or expression signatures for early assessment of predicted outcome as a result of disease or injury. Because burns, trauma, and critical illness involve multiple organs, a reliable high-throughput method to assess the systemic response-such as profiling the plasma proteomewould aid in identification of biomarkers, therapeutic targets, proteins with unexpected participation in outcome, and outcome signatures. Measurement of these proteins may be complicated by variable protein abundance due to biological heterogeneity, a broad dynamic range covering more than ten orders of magnitude, and the complexity of the plasma proteome (3) . Despite recent advances in liquid chromatographymass spectrometry (LC-MS) approaches that have the potential to compensate for these confounders, this platform is often not robust enough to offer the high reproducibility required for large-scale clinical studies (3) . Therefore, an effective method for evaluating the reproducibility among the large number of biological analytes is essential. Here, we describe the novel application of quantitative, large-scale proteomic profiling via LC-MS coupled with multiplex cytokine measurement to establish a plasma proteome survival signature and to discover new candidate plasma biomarkers for survival of a severe burn injury. The use of an 18 O-labeled "universal" reference sample enables quantitation with concurrent evaluation of reproducibility, while allowing the simultaneous integration of a labeled approach with the label-free approach for quantitation (4) . Furthermore, we propose that proteomic outcome signatures may reveal new drug targets in the form of proteins or pathways previously unknown to play a role in the disease or injury process and that a patient's proteomic survival signature and outcome trajectory may be altered via therapeutic intervention.
MaterIals anD MethODs

Patients
The study, a part of the Inflammation and the Host Response Glue Grant, was approved by the Institutional Review Boards of the University of Texas Medical Branch (Galveston, TX), Loyola University Medical College (Chicago, IL), University of Texas Southwestern (Dallas, TX), University of Washington Seattle (Seattle, WA), and Massachusetts General Hospital (Boston, MA). Seventy-five patients who were enrolled from 2000 to 2005 and met the following criteria were considered for inclusion in this study: year olds, admitted within 96 hours after injury to the participating hospitals, and had burns covering more than 20% of the total body surface area requiring at least one surgical intervention. After admission, patients were treated according to the standard of burn care established by this consortium (5) . Each subject or family member signed a written informed consent form. Blood was drawn between postburn days 0 and 19 for plasma isolation. Demographics (age, dates of burn and admission, gender, burn size, and depth of burn) and concomitant injuries, such as inhalation injury, infection, morbidity, and mortality were recorded prospectively throughout hospital course. The patients were retrospectively divided into two groups-survivors and nonsurvivors. Survivors and nonsurvivors were matched based on age, burn size, burn mechanism, sex, and ethnicity. Patients in both groups arrived at the participating hospitals at similar postburn times, received similar hospital care, and had a similar time from burn to resuscitation.
sample handling
The protocol calls for blood drawn at the time of surgical intervention on an approximate weekly basis. Peripheral blood samples were collected prior to the induction of anesthesia and processed within 1 hour of being drawn as previously described (6, 7) . To minimize the effect of temporal expression, we selected blood samples drawn 7 days or more prior to death and chose a sample from a similar time point (postburn days 0-19) for the matched surviving patient. One nonsurviving patient had a single plasma sample at postburn day 19, so that sample was used.
Quantitative Proteomic strategy
An integrated LC-MS-based proteomic strategy that incorporates an 18 O-labeled "universal" reference sample for achieving reliable quantitation was used to profile patient plasma (4) (Supplemental Fig. 1 , Supplemental Digital Content 1, http:// links.lww.com/CCM/A597). The 18 O-labeled "universal" reference sample served as a comprehensive internal standard in each sample, enabling isotope labeling-based quantification of relative protein abundances in patients relative to the reference and facilitating better evaluation of the platform reproducibility for normalization of the label-free abundance data. The label-free and isotope labeling-based dual quantitation approaches can be applied simultaneously to take advantage of their complementariness to achieve robust quantitation.
The overall dynamic measurement range was enhanced by integrating immunoaffinity chromatography for removing the 12 most abundant proteins in human plasma (8) and a cysteinyl peptide enrichment-based fractionation at the peptide level (9) with an automated high-resolution LC-MS system. The overall throughput of analysis is only slightly compromised since the strategy only produces two fractions per patient sample. Peptide features detected by LC-MS are identified by matching the detected accurate masses and normalized elution times to a pre-established accurate mass and time (AMT) tag database applying the AMT tag strategy (10) . The peptide AMT tag database was established based on an extensive LC-MS/ MS survey of pooled trauma patients as previously described (11) ; the database includes the calculated masses and normalized elution times for all identified peptides, so that the database serves as a "look-up table" for identifying peptides from LC-MS analyses using the AMT tag approach. Quantitative information for each identified feature was extracted based on either isotope 16 O/ 18 O ratios or label-free 16 O-MS intensities.
Plasma Protein Processing and lC-Ms analysis
The initial protein concentration for each sample was determined by Coomassie protein assay (Pierce, Rockford, IL). A reference peptide sample was generated by pooling 100 µL of plasma from each patient. The patient samples and the pooled reference sample were individually depleted of the 12 most abundant plasma proteins (albumin, IgG, α1-antitrypsin, IgA, IgM, transferrin, haptoglobin, α1-acid glycoprotein, α2macroglobulin, apolipoprotein A-I, apolipoprotein A-II, and fibrinogen) using a prepacked ProteomeLab IgY-12 affinity LC-10 column (Beckman Coulter, Fullerton, CA) on an Agilent 1100 series HPLC system (Agilent, Santa Clara, CA). The flow-through fractions were then individually concentrated using iCON concentrators (Pierce) and digested with trypsin. Immunoaffinity depletion and plasma protein digestion were performed as previously described (8) .
The peptides from the reference sample were labeled by stable isotope 18 O via trypsin-catalyzed 18 O labeling as previously described (10) . Identical aliquots of labeled reference peptides were then mixed with an equal amount of each individual patient sample, so that each final processed patient sample contained an identical reference sample. Each mixed patient sample was then fractionated as described (11) . All final peptide fractions were then analyzed using a fully automated custom-built capillary LC platform coupled online using an in-house-manufactured Enclosure Services Interface to an 11.5 T Fourier transform ion cyclotron resonance (FTICR) mass spectrometer similar to as previously described (10) .
Proteomic Data Processing
Analyses of datasets obtained from quantitative LC-FTICR were performed as previously described (10, 12) . The AMT tag database was established based on those peptides and proteins previously identified in the trauma patient plasma proteome (11) . Peptides were identified in the AMT tag database based on the normalized elution times and accurate mass measurements within a 2.5-ppm mass error and a 2% normalized elution time error. All identified peptides were reported for their 16 O/ 18 O isotopic ratios in addition to the label-free 16 O-MS intensities. The 16 O/ 18 O ratio data and label-free intensity data were processed separately. The median of 16 O/ 18 O ratios (log 2 scale) was normalized to zero to correct potential errors in mixing the labeled reference and patient samples. The labelfree intensity data were also normalized across the patients using the central tendency global normalization technique (13) . The data from cysteinyl and noncysteinyl fractions for each patient were combined, and the corresponding proteins or protein groups determined using the software tool Protein-Prophet (Institute for Systems Biology, Seattle, WA) (14) . Two separate datasets were generated for statistical analysis of the proteomic difference. One dataset contained 16 
statistical analysis of Proteomic Data
Patient (label-free 16 O intensity) data were filtered to remove peptides that mapped to more than one protein group and peptides that were not observed in more than half of the samples from at least one of the patient groups. The intensities were then scaled to the protein concentration and normalized to the reference intensities. The resulting matrix was then permuted 1,000 times, and the intensity difference between nonsurvivors and survivors was calculated in each permutation. The number of times the observed ranked difference exceeded the null difference was used to generate a p value. Principal components analysis was performed using peptide features from the significant proteins.
Plasma Cytokine Measurement
Plasma concentrations of 22 cytokines were measured using the Linco Research multiplex bead array and analyzed using MiraiBio software. Unpaired Student t tests were used to compare differences in cytokine expression.
Pathway analysis
Protein annotations were obtained through a review of National Center for Biotechnology Information databases and the Ingenuity Pathways Knowledge Base (http://www.ingenuity.com). The Ingenuity Pathways Knowledge Base was used to overlay the concentration changes of significant proteins on the genomic and proteomic networks of previously known interactions between human orthologs (6) .
resUlts
Patients
Of the 75 patients meeting the study criteria, 19 were nonsurvivors. Two who died in nursing homes after discharge and one who died the day of injury were excluded from the analysis to minimize variation in time after injury and prior to death. There were no significant differences between nonsurvivors (n = 16) and matched survivors (n = 16) in age, percent thirddegree burn, burn mechanism, or sex ( Table 1) . Although there was a small but significant difference in total burn size (total body surface area burned: 63% ± 21%, nonsurvivors vs. 49% ± 16%, survivors, p = 0.03), the full-thickness burn extent was comparable. Nonsurviving patients died within 32 ± 19 days of burn. Causes of death are shown in Supplemental Table 1 (Supplemental Digital Content 2, http://links.lww.com/CCM/ A598). Eight patients died of multiple organ failure, and eight patients of cardiac dysfunction; sepsis was a cause or cocause of death in nine patients.
lC-Ms Platform Performance
We performed a total of 64 LC-MS analyses. The assessment of platform reproducibility based on the pairwise correlation of The estimated dynamic range for this platform is ~10 5 , allowing the detection of concentrations of ~500 ng/mL (3). Low-abundance proteins (1-100 ng/mL) were detected and included platelet factor 4, cathepsin d, metalloproteinase inhibitor 1, insulin-like growth factor-binding protein 2, insulin-like growth factor 1, and hepatocyte growth factor-like protein.
Identification of Proteins through lC-Ms
A total of 4,163 different peptides corresponding to 602 different plasma proteins were identified (strategy outlined in Supplemental Fig. 1 , Supplemental Digital Content 1, http://links. lww.com/CCM/A597). Thirty-nine proteins were differentially detected in survivors and nonsurvivors ( Table 2) . Fold changes (nonsurvivors to survivors) were calculated for the 201 proteins that were detected in samples from both survivors and nonsurvivors ( Table 3) .
Unsupervised methods (e.g., hierarchical clustering or principal components analyses) did not demonstrate separation according to survival, indicating that other factors aside from survival determine the majority of differences in protein abundance in the dataset. The 39 proteins that were significantly different between the cohorts clustered according to survival.
Cytokine Differences between nonsurvivors and survivors Detected by Multiplex technology
Cytokine measurement revealed that interleukin (IL)-4, IL-8, granulocyte macrophage colony-stimulating factor (GM-CSF), and monocyte chemotactic protein (MCP)-1 were significantly higher in nonsurvivors than in survivors (p < 0.05 for all, Fig. 1 ). There were no differences in circulating levels of the 18 additional cytokines (Supplemental Table 2 , Supplemental Digital Content 2, http://links.lww.com/CCM/A598).
Biological Implications of the Proteomic survival signature
The 43 proteins (39 identified by mass spectrometry and four by multiplex cytokine analysis) were used to create a proteomic survival signature. To determine which biological pathways are implicated by the proteins expressed differentially between the two patient populations, we examined the 43 proteins using the Ingenuity Pathway Knowledge Base. The proteins were associated with the following biological functions (n): inflammatory disease (13), cell movement (15), hematological system development and function (17), immune response (16) (13) , immune and lymphatic system function and development (12) , tissue development (14), molecular transport (15), and cell signaling (16) . We further examined signaling pathways to identify the tissues involved in the systemic response to burn. The main canonical pathways that were affected were the coagulation cascade, the complement response, hepatic acute-phase response signaling, and inflammatory cytokine pathways. Proteins in the coagulation cascade were downregulated (factor 2, factor 13B, plasminogen, and SERPINC1), while factor 10 was upregulated in nonsurvivors. Proteins active in the complement cascade were downregulated in nonsurvivors (Complement components 9, 8A, 8B, and complement factor 1). Proteins active in acute-phase response signaling and/or inflammatory cytokine signaling were detected at higher levels in nonsurvivors (IL-4, IL-8, and CCL2), while SERPINA3, factor 2, plasminogen, and complement component 9 were more abundant in survivors. In the glucocorticoid receptor signaling pathways, CCL2, CSF2, IL-4, and IL-8 were upregulated in nonsurvivors. The activity of the proteins in the complement cascade, coagulation cascade, acute-phase response pathway, and cytokine signaling suggests that the response of the liver may be crucial to survival following a burn injury. Use of a networking tool that permits visualization of interactomes revealed that 13 of the 43 proteins interact directly with each other; IL-8, CCL-2, and F2 are the central molecules through which IL-4, LPA, CD44, plasminogen, SERPINC1, PPBP, HABP2, F10, CSF2, and B2M are linked (Supplemental Fig. 3 , Supplemental Digital Content 4, http://links. lww.com/CCM/A600), suggesting that therapies designed to modulate the expression or interactions of these proteins might affect patient outcome.
Orthogonal Candidate Biomarker Measurement
We measured a subset of the LS-MS-identified proteins to determine whether standard clinical laboratory techniques could be used to detect differences in protein abundance between surviving and nonsurviving patients. β2-Microglobulin, apolipoprotein A, factor X, prothrombin, complements C8 and C9, antithrombin 3, and plasminogen were selected as candidates for orthogonal validation based on the p-values and peptidefold change data. β2-Microglobulin was found to be decreased in nonsurvivors using nephelometry (p < 0.05), confirming the LC-MS data. Given the small sample sizes and sample preprocessing steps in the LC-MS not used in the clinical laboratory, confirmation of one of the proteins to a statistically significant degree was notable.
DIsCUssIOn
After severe burn, the major causes of death, particularly in adult and elderly patients, are infectious and septic complications resulting from organ dysfunction. The postburn hypermetabolic response frequently leads to multiorgan failure and septic complications, increasing morbidity and mortality in the burn patient population. The hypermetabolic response is driven by systemic inflammation mediated by cytokines and acute-phase proteins. Although the burn size differed between the patient groups, the severity of the burn was the same. Several studies have demonstrated that the third-degree component is more important for the prediction of outcome than is the total body surface area burned (1, (16) (17) (18) . Our data confirm this and strongly support the central role of the liver in survival from a severe burn injury. Forty-three proteins were significantly altered in the plasma proteome of nonsurvivors compared with survivors, including coagulation proteins, adhesion molecules, inflammatory markers, metabolic markers, and hepatic acute-phase proteins. Although this is the first time that many of these proteins have been associated with a burn injury, the physiological processes that they represent are required for recovery from any disease or traumatic injury. The response to a burn injury requires an intact coagulation cascade for survival. Hypercoagulation with subsequent increased consumption of coagulation factors leads to disseminated intravascular coagulation, which is characterized by decreased levels of plasminogen and coagulation factor XIII in nonsurvivors. Therapeutic modulation of hypercoagulability may improve burn survival, as suggested by the clinical trial of drotrecogin alfa, recombinant activated C in patients with septic shock (19, 20) . Hypercoagulation and disseminated intravascular coagulation occur alongside increased inflammation and abundance of adhesion molecules. Vascular cell adhesion molecule 1, a major cell adhesion molecule, is markedly increased in nonsurvivors immediately postburn. White blood cells adhere to the endothelium and subsequently diapedese through the blood vessel wall, releasing inflammatory molecules, such as metalloproteinases and cytokines into the tissue. Inflammatory markers, such as TIMP-1, GM-CSF, IL-4, IL-8, and MCP-1 are upregulated in nonsurvivors, indicating a greater inflammatory response in nonsurvivors and confirming our results from a genomic analysis of white blood cells (Lancet, under review). These markers are also associated with insulin resistance and metabolic derangements. Markers of insulin resistance, such as retinol-binding protein 4, sex hormone-binding globulin, CD-14, glycosylphosphatidylinositol-specific phospholipase D1, and proplatelet basic protein were increased in nonsurvivors. The complement system is also deranged in nonsurvivors. Significant decreases in complement component 1, complement factor D, complement 8, and complement 9 in nonsurvivors further support the notion that hyperinflammatory and hyperimmune responses are modulated differently in nonsurvivors, ultimately contributing to immune compromise, subsequent infection, and septic complications.
The majority of the 43 proteins associated with burn survival are produced in the liver, supporting the hypothesis that the liver plays a central role in the postburn response as well as in determining survival. The liver's metabolic, inflammatory, immune, and acute-phase functions play a pivotal role in recovery from injury by modulating multiple pleiotropic pathways. The hepatic acute-phase response is characterized by an increase in production of acute-phase proteins coupled with a failure to produce constitutive proteins. This shift in hepatic protein synthesis leads to physiologic alterations in transport, metabolic, and immune functions, which may prove to be useful for predicting survival. A study of 31,338 burn patients demonstrated that healthy liver function is essential for survival following traumatic injury (21) . A subgroup analysis of 180 patients with liver disease prior to the burn injury revealed a six-to eight-fold increase in mortality with pre-existing liver dysfunction. Our study supports this conclusion and further suggests that the secretion of liver-derived proteins can be used as predictive markers for survival or as part of the proteomic survival signature in severely burned patients. Furthermore, the differentially expressed proteins indicate that hepatic insulin resistance accompanies postburn peripheral insulin resistance. That insulin therapy may be acting to overcome hepatic insulin resistance may explain why insulin therapy improves morbidity and mortality in severely burned as well as critically ill patients (22) (23) (24) .
Our study demonstrates that the integrated LC-MS-based quantitative proteomic discovery approach can be used to successfully identify candidate proteins for classification of patient outcomes, whether for use in establishing proteomic outcomes signatures or to distinguish proteins that will serve as potential biomarkers or targets for therapeutic intervention. The plasma proteomics-based discovery efforts have traditionally been challenged by lack of reproducibility of quantitative results, low dynamic range of detection, and low sample throughput. The present large-scale quantitative strategy was enabled by the incorporation of a stable isotope labeled "universal" reference sample into each patient sample, which provided an effective means for assessing the reproducibility of large-scale sample analyses (4) . The labeled reference sample also enabled the application of isotope-labeling-based quantitation across an unlimited number of samples, distinguishing this technique from traditional labeling approaches, which are always limited to pairwise comparisons or comparison between a few conditions. The simultaneous integration of the two quantitative approaches into a single strategy also enhanced the overall confidence of the quantitative data by providing cross-validation between the two approaches. The current quantitative strategy can also be effectively integrated with the immunoaffinity chromatography and cysteinyl peptide enrichment-based limited fractionation with high resolution LC-MS to offer relatively high dynamic range measurements (greater than 10 5 ) for achieving good proteome coverage and the throughput necessary for analyzing a large number of samples in a relatively short time. Low-molecular weight and low abundance proteins, such as cytokines cannot be effectively detected via LC-MS methods. By augmenting the LC-MS technique with multiplex cytokine analysis, we can reliably detect the plasma proteome alterations that accompany the response to injury. However, because our cytokine assay only measures a select number of known cytokines, the likelihood of missing expression differences for other nonmeasured cytokines, or additional low-molecular weight or low abundance proteins, is highly likely. Development of techniques to adequately assess these classes of proteins would allow full interrogation of the postburn plasma proteome.
Because a huge immunoinflammatory response accompanies a burn, trauma, or critical illness, high-throughput multiplex cytokine measurement was performed to determine whether complementary information regarding protein abundance could be used to build the proteomic survival signature. Proinflammatory cytokines have been suggested as potential biomarkers for outcome and as targets for interventional trials. Multiplex cytokine measurement has been used to successfully predict patient outcomes as well (25, 26) , although attempts to alter cytokine expression to date have failed to improve patient outcomes. This combination of quantitative proteomic strategies has allowed us to quantitatively measure more than 600 proteins in samples from 32 patients; 43 proteins were identified as significantly differing between the patient cohorts, demonstrating a role for discovery proteomics in treating critical illness.
One drawback to this study was the small patient numbers. This was due to the lack of nonsurvivors enrolled in the program, as the intent to treat the patient is one of the enrollment criteria. Additional studies with larger patient numbers will be necessary to confirm the results reported here and to further develop this LC-MS approach. Future efforts may focus on determining whether the plasma protein profiles vary based on the cause of death. At this point, however, the numbers of patients are too small. Furthermore, in light of the potential demonstrated in our small patient cohort, studies are being currently conducted with larger patient numbers to investigate outcomes that are not as clearly determined such as multiorgan failure. A further concern about this study is the difficulty in orthogonally validating the proteins identified by LC-MS. This may be due to the following: large biological variation in a small dataset; removal of binding proteins (e.g., albumin) prior to LC-MS, which leads to the removal of additional proteins that can still be detected via clinical assays; the inability of antibodybased technologies to recognize the protein identified by LC-MS due to epitope masking; or the inability of the peptide database to distinguish between the presence of multiple isoforms of a particular protein. That β2-microglobulin was confirmed as a potential biomarker using traditional techniques demonstrated that the LC-MS platform can be used to identify targets for confirmation in further studies with larger patient numbers.
COnClUsIOns
This study supports the utility of the quantitative LC-MS technique used here in discovering proteins relevant to critical illness, defining proteome signatures, and identifying potential biomarkers. High-throughput proteomic screening techniques, such as the quantitative LC-MS technique may provide mechanistic insight into the clinical phenomenon that stress, injury, or acute illness can induce insulin resistance. Considering that post injury loss of more than 30% to 40% of lean body mass is associated with 100% mortality (27) , the proteomic survival signature may also yield important clues regarding the mechanisms of survival. Finally, the finding that the majority of the 43 proteins with differential abundances between nonsurvivors and survivors had not been previously associated with the burn response let alone with survival illustrates the applicability of LC-MS and multiplex cytokine analysis for detecting potential biomarkers and concurrently defining a proteomic outcome signature. This provides for the possibility of improving clinical management and enabling development of successful interventions that alter outcome trajectories and decrease mortality after a severe burn.
